Pieris: Servier deals blow to Pieris as oncology collab comes to end

In a filing with the US Securities and Exchange Commission (SEC), Pieris Pharmaceuticals (Nasdaq: PIRS) has notified investors that Servier Laboratories is pulling the plug on the firms' cancer collaboration.